Newsletter | October 1, 2026

10.01.26 -- Why CDMO Capacity Investments Signal A New Era In Cell & Gene

SPONSOR

 

Webinar: Precision at Scale: Optimizing Cell-Free DNA Manufacturing for Next-Generation mRNA Vaccines and Therapeutics

As mRNA vaccines and therapeutics advance, scalable, consistent DNA templates are increasingly important. This 4basebio webinar explores 4basebio’s cell-free, enzymatic synthetic DNA platform and how it can support high-quality IVT templates, reduce impurities and aberrant RNA species, and enable stable, continuous poly(A) sequences up to 180 nucleotides. Discover new approaches for next-generation mRNA manufacturing. Click here to learn more.

FOCUS ON OUTSOURCING

Building CGT Manufacturing Capacity For The Next Commercial Era

By Lynette Nazabal and Riley Welch, Clarkston Consulting

Recent investments — mostly by CDMOs — are expanding manufacturing capacity to support the growing cell and gene therapy pipeline. We also discuss associated trends and impacts.

 

 

Advanced AAV Analytics To Improve Accuracy And Speed Development

Article | Andelyn Biosciences

Assess genome integrity and capsid traits using multiplex analytics. Upgrade your testing methods to improve accuracy, accelerate development, and strengthen regulatory control.

 

Why The Traditional Approach To Evaluating Gene Editing Is Not Your Only Option

White Paper | By Larry Lockwood, ElevateBio

De-risk genetic medicine development with a phased evaluation approach. Gain rapid, data-driven feasibility insights before major investments, enabling smarter decisions and faster clinical progress.

 

The New Rules Of Developing Novel AAV Capsids

Q&A | Viralgen

Engineered capsids expand therapeutic reach. Success requires integrating analytical readiness, manufacturability, immunogenicity, and regulatory strategy from early selection.

 

How To Design And Evaluate Bispecific Antibodies (BsAbs)?

White Paper | ProBio

Bispecific antibodies combine two antigen-binding sites to enhance efficacy and safety. Their design requires structural strategy, MOA-based evaluation, and rigorous screening for optimal therapeutic performance.

 

Using Synthetic ssDNA And dsDNA Templates For CRISPR Editing

Article | 4basebio

Synthetic ssDNA and dsDNA donor templates boost CRISPR precision, efficiency, and consistency. The right strategy reduces errors, increases HDR, and delivers more reliable results across applications.

OUTSOURCING SOLUTIONS

•

Complete GMP iPSC & MSC Manufacturing - Applied StemCell

•

The CRO Accelerating Bioanalysis With Speed, Precision, And Impact - Dash Bio

•

Comprehensive Cell And Gene Therapy CDMO Services - Miltenyi Bioindustry
Connect With Cell & Gene: